Dr. Craig Shimasaki, President and CEO, Moleculera Labs, reviews the science behind immune-mediated neuropsychiatric disorders and how testing with the Cunningham Panel for antineuronal antibodies can assist in diagnosis and in directing treatment.
Chapters:
2:32 - Start of presentation
4:30 - Neuropsychiatric disorders diagnosed by symptoms, not etiology
6:15 - Can infections cause neuropsychiatric disorders?
7:59 - Rheumatic fever triggered by strep infection
9:42 - Neuronal autoantibodies
9:50 - How does this occur biologically?
13:16 - Study: Brain inflammation on MRI in children with OCD/tics associated with strep infection
15:49 - Other immune-mediated disorders
17:10 - Infections frequently associated with autoimmune encephalopathies
17:29 - Antibodies recognize ‘epitopes’ on infectious agents
20:19 - Molecular mimicry and strep
25:25 - Review of Cunningham Panel assays
27:31 - Case studies of patients tested with the Cunningham Panel
33:21 - Commonalities in patients with antineuronal antibodies
35:10 - Study: Evaluation of the Cunningham Panel
37:41 - Ordering & testing process - Cunningham Panel
38:24 - Treatment Guidelines for PANS/PANDAS
46:16 - Q&A
46:24 - After initiating treatment for infection, when do you expect antibodies to go down and when should you retest?
48:34 - What is an alternative for IVIG because we don’t know if it’s been effected by vaccinated blood supply.
51:49 - Can you speak to the testing before and after on the group that did not respond to treatment? (In reference to a 58 patient case study)
54:24 - Are PET scans often done on these patients and what do they typically show?
26 авг 2024
